海泰新光：公司信息更新报告：2025年业绩高增，海外布局持续推进-20260301

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to achieve significant revenue growth in 2025, with projected revenue of 603 million yuan, representing a year-on-year increase of 36.08%. The net profit attributable to the parent company is forecasted to be 172 million yuan, up 26.79% year-on-year [4] - The company is expanding its overseas production capacity, particularly in Thailand, which is expected to enhance its resilience against risks and improve operational efficiency [6] - The demand for medical endoscope products is increasing, and the company is actively developing new products in collaboration with clients in the optical and medical fields [5] Financial Summary - Revenue is projected to grow from 471 million yuan in 2023 to 603 million yuan in 2025, with a compound annual growth rate (CAGR) of 36.1% [7] - The net profit attributable to the parent company is expected to rise from 146 million yuan in 2023 to 172 million yuan in 2025, reflecting a year-on-year growth of 26.9% [7] - The company's gross margin is anticipated to improve from 63.7% in 2023 to 66.2% in 2025, indicating better cost management and pricing power [7]